The reviewed documents unanimously recommend the use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, SGLT2 inhibitors, and diuretics for treating heart failure, consistent with the heart failure guidelines issued by ESC in 202115 and by AHA/ACC in 2016.16 Additionally, HRS document specify a Class IIb indication for isosorbide dinitrate to reduce preload in cases of right ventricular failure.12 The gene discussed is SLC5A2; the disease is heart failure.